Relationship between subcutaneous fat distribution and serum lipids and blood pressures in italian men

1994 ◽  
Vol 6 (4) ◽  
pp. 457-463 ◽  
Author(s):  
Marcella Folin ◽  
Eva Contiero
2007 ◽  
Vol 30 (4) ◽  
pp. 86
Author(s):  
M. Lanktree ◽  
J. Robinson ◽  
J. Creider ◽  
H. Cao ◽  
D. Carter ◽  
...  

Background: In Dunnigan-type familial partial lipodystrophy (FPLD) patients are born with normal fat distribution, but subcutaneous fat from extremities and gluteal regions are lost during puberty. The abnormal fat distribution leads to the development of metabolic syndrome (MetS), a cluster of phenotypes including hyperglycemia, dyslipidemia, hypertension, and visceral obesity. The study of FPLD as a monogenic model of MetS may uncover genetic risk factors of the common MetS which affects ~30% of adult North Americans. Two molecular forms of FPLD have been identified including FPLD2, resulting from heterozygous mutations in the LMNA gene, and FPLD3, resulting from both heterozygous dominant negative and haploinsufficiency mutations in the PPARG gene. However, many patients with clinically diagnosed FPLD have no mutation in either LMNA or PPARG, suggesting the involvement of additional genes in FPLD etiology. Methods: Here, we report the results of an Affymetrix 10K GeneChip microarray genome-wide linkage analysis study of a German kindred displaying the FPLD phenotype and no known lipodystrophy-causing mutations. Results: The investigation identified three chromosomal loci, namely 1q, 3p, and 9q, with non-parametric logarithm of odds (NPL) scores >2.7. While not meeting the criteria for genome-wide significance, it is interesting to note that the 1q and 3p peaks contain the LMNA and PPARG genes respectively. Conclusions: Three possible conclusions can be drawn from these results: 1) the peaks identified are spurious findings, 2) additional genes physically close to LMNA, PPARG, or within 9q, are involved in FPLD etiology, or 3) alternative disease causing mechanisms not identified by standard exon sequencing approaches, such as promoter mutations, alternative splicing, or epigenetics, are also responsible for FPLD.


1980 ◽  
Vol 60 (2) ◽  
pp. 223-230 ◽  
Author(s):  
S. D. M. JONES ◽  
R. J. RICHMOND ◽  
M. A. PRICE ◽  
R. B. BERG

The growth and distribution of fat from 163 pig carcasses were compared among five breeds (Duroc × Yorkshire (D × Y), Hampshire × Yorkshire (H × Y), Yorkshire (Y × Y), Yorkshire × Lacombe-Yorkshire (Y × L-Y) and Lacombe × Yorkshire (L × Y)) and two sex-types (barrows and gilts) over a wide range in carcass weight. The growth pattern of fat and the fat depots were estimated from the allometric equation (Y = aXb) using side muscle weight and side fat weight separately as independent variables. Growth coefficients (b) for intermuscular and subcutaneous fat depots were similar for the hindquarter but the intermuscular depot coefficient was slightly higher for the forequarter. The coefficient for body cavity fat was highest in all comparisons. No significant differences were detected for coefficients among breeds and between sexes using both total muscle and total side fat as independent variables. Significant breed and sex-type differences were found in the fat depots at a constant weight of side muscle. This would indicate that breed differences in fatness seemed to be more influenced by the initiation of fattening at different muscle weights than by any inherent differences in rate of fattening. Significant breed differences were also found in the fat depots at a constant fat weight, indicating that breed may influence fat distribution. Sex-type had no effect on fat distribution when the evaluation was made at constant fatness.


1989 ◽  
Vol 130 (1) ◽  
pp. 53-65 ◽  
Author(s):  
JACOB C. SEIDELL ◽  
MASSIMO CIGOLINI ◽  
JADVIGA CHARZEWSKA ◽  
BRITT-MARIE ELLSINGER ◽  
GIUSEPPE DI BIASE ◽  
...  

2012 ◽  
Vol 166 (3) ◽  
pp. 469-476 ◽  
Author(s):  
L Frederiksen ◽  
K Højlund ◽  
D M Hougaard ◽  
T H Mosbech ◽  
R Larsen ◽  
...  

ObjectiveTestosterone therapy increases lean body mass and decreases total fat mass in aging men with low normal testosterone levels. The major challenge is, however, to determine whether the metabolic consequences of testosterone therapy are overall positive. We have previously reported that 6-month testosterone therapy did not improve insulin sensitivity. We investigated the effect of testosterone therapy on regional body fat distribution and on the levels of the insulin-sensitizing adipokine, adiponectin, in aging men with low normal bioavailable testosterone levels.DesignA randomized, double-blinded, placebo-controlled study on 6-month testosterone treatment (gel) in 38 men, aged 60–78 years, with bioavailable testosterone <7.3 nmol/l, and a waist circumference >94 cm.MethodsCentral fat mass (CFM) and lower extremity fat mass (LEFM) were measured by dual X-ray absorptiometry. Subcutaneous abdominal adipose tissue (SAT), visceral adipose tissue (VAT), and thigh subcutaneous fat area (TFA) were measured by magnetic resonance imaging. Adiponectin levels were measured using an in-house immunofluorometric assay. Coefficients (b) represent the placebo-controlled mean effect of intervention.ResultsLEFM was decreased (b=−0.47 kg, P=0.07) while CFM did not change significantly (b=−0.66 kg, P=0.10) during testosterone therapy. SAT (b=−3.0%, P=0.018) and TFA (b=−3.0%, P<0.001) decreased, while VAT (b=1.0%, P=0.54) remained unchanged. Adiponectin levels decreased during testosterone therapy (b=−1.3 mg/l, P=0.001).ConclusionTestosterone therapy decreased subcutaneous fat on the abdomen and lower extremities, but visceral fat was unchanged. Moreover, adiponectin levels were significantly decreased during testosterone therapy.


Author(s):  
Raj S. Bhopal

Central body fat has been shown to be metabolically harmful while peripheral fat is neutral or even beneficial. The adipose tissue (compartment) overflow and the variable disease selection hypotheses aim to explain why South Asians tend to central adiposity. The former proposes it results from a small superficial subcutaneous fat compartment especially in the lower limbs, so excess energy is deposited as fat in central compartments. The evolutionary forces for this are presumed to be climatic. The latter proposes central fat deposits in South Asians are an evolutionary adaptation to combat gastrointestinal infections. South Asians’ also have small muscle mass, and small hips, for which there are no well-defined hypotheses. The small size at birth of South Asians may be relevant to all these observations. These differences in fat distribution, muscle and skeletal structure could explain a tendency to central (apple-shaped) obesity than generalized or peripheral obesity (pear-shaped).


2020 ◽  
Vol 2020 ◽  
pp. 1-12 ◽  
Author(s):  
Da Yao ◽  
Qing Chang ◽  
Qi-Jun Wu ◽  
Shan-Yan Gao ◽  
Huan Zhao ◽  
...  

Objective. Nowadays, body mass index (BMI) is used to evaluate the risk stratification of obesity-related pregnancy complications in clinics. However, BMI cannot reflect fat distribution or the proportion of adipose to nonadipose tissue. The objective of this study is to evaluate the association of maternal first or second trimester central obesity with the risk of GDM. Research Design and Methods. We searched in PubMed, Embase, and Web of Science for English-language medical literature published up to 12 May 2019. Cohort studies were only included in the search. Abdominal subcutaneous fat thickness, waist circumference, waist-hip ratio or body fat distribution were elected as measures of maternal central obesity, and all diagnostic criteria for GDM were accepted. The random effect meta-analysis was performed to evaluate the relationship between central obesity and the risk of GDM. Results. A total of 11 cohort studies with an overall sample size of 27,675 women and 2,226 patients with GDM were included in the analysis. The summary estimate of GDM risk in the central obesity pregnant women was 2.76 (95% confidence interval [CI]: 2.35–3.26) using the adjusted odds ratio (OR). The degree of heterogeneity among the studies was low (I2=14.4, P=0.307). The subgroup analyses showed that heterogeneity was affected by selected study characteristics (methods of exposure and trimesters). After adjusting for potential confounds, the OR of adjusted BMI was significant (OR=3.07, 95% CI: 2.35–4.00). Conclusions. Our findings indicate that the risk of GDM was positively associated with maternal central obesity.


2003 ◽  
Vol 11 (2) ◽  
pp. 202-208 ◽  
Author(s):  
Saskia J. te Velde ◽  
Jos W.R. Twisk ◽  
Willem van Mechelen ◽  
Han C.G. Kemper

2007 ◽  
Vol 157 (2) ◽  
pp. 167-174 ◽  
Author(s):  
Soo-Kyung Kim ◽  
Kyu-Yeon Hur ◽  
Hae-Jin Kim ◽  
Wan-Sub Shim ◽  
Chul-Woo Ahn ◽  
...  

Objective: The goal was to investigate the interrelationships between the hypoglycemic effects of rosiglitazone and the changes in the regional adiposity of type 2 diabetic patients. Design and methods: We added rosiglitazone (4 mg/day) to 173 diabetic patients (111 males and 62 females) already taking a stable dose of conventional antidiabetic medications except for thiazolidinediones. The abdominal fat distribution was assessed by ultrasonography at baseline and 12 weeks later. Using ultrasonographic images, the s.c. and visceral fat thickness (SFT and VFT respectively) were measured. Results: Rosiglitazone treatment for 3 months improved the glycemic control. However, the response to rosiglitazone was no more than 36.4%; the deterioration of the glycemic control was found in 16.8% of subjects. In addition, rosiglitazone treatment significantly increased the body fat mass, especially the s.c. fat. However that did not alter the visceral fat content. The percentage changes in fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) concentrations after treatment were inversely correlated with the increase in SFT (r=−0.327 and −0.353, P<0.001 respectively) and/or body weight (r=−0.316 and −0.327, P<0.001 respectively). Multiple regression analysis revealed that the improvement in the FPG after rosiglitazone treatment was correlated with the baseline FPG (P<0.001) and the change in the SFT (P=0.019), and the reduction in the HbA1c was related with the baseline FPG (P=0.003) and HbA1c (P<0.001) and the changes in the SFT (P=0.010) or VFT (P=0.013). Conclusions: The increase in the s.c. fat depot after rosiglitazone treatment may be an independent factor that determines the hypoglycemic efficacy.


Sign in / Sign up

Export Citation Format

Share Document